Ultragenyx sold a priority review voucher for $210 million to an undisclosed buyer, marking one of the richest PRV monetizations reported this year. The company said it still has another voucher available to monetize, keeping flexibility for future regulatory and development planning. For developers and investors in rare disease, PRV monetizations can materially affect runway and capital strategy—particularly for sponsors balancing late-stage costs against the timing of potential approvals. The deal also signals that the market for accelerated-approval instruments remains active even as development risk and pricing debates continue to reshape specialty oncology and rare-disease financing.